Salarius Pharmaceuticals, Inc.
SLRX
$0.698
-$0.0348-4.75%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -13.23% | -30.91% | -25.23% | -22.38% | -19.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -55.53% | -71.65% | -68.63% | -58.50% | -43.87% |
| Operating Income | 55.53% | 71.65% | 68.63% | 58.50% | 43.87% |
| Income Before Tax | 55.55% | 72.31% | 78.45% | 71.09% | 60.32% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 55.55% | 72.31% | 78.45% | 71.09% | 60.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 55.55% | 72.31% | 78.45% | 71.09% | 60.32% |
| EBIT | 55.53% | 71.65% | 68.63% | 58.50% | 43.87% |
| EBITDA | 55.53% | 71.66% | 68.66% | 58.53% | 43.89% |
| EPS Basic | 79.57% | 85.66% | 87.75% | 80.15% | 69.22% |
| Normalized Basic EPS | 79.57% | 85.66% | 82.36% | 72.10% | 57.97% |
| EPS Diluted | 79.57% | 85.66% | 87.75% | 80.15% | 69.22% |
| Normalized Diluted EPS | 79.57% | 85.66% | 82.36% | 72.10% | 57.97% |
| Average Basic Shares Outstanding | 140.69% | 108.80% | 73.86% | 61.61% | 50.70% |
| Average Diluted Shares Outstanding | 140.69% | 108.80% | 73.86% | 61.61% | 50.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |